The ATP Binding Cassette Sub Family A Member 1 pipeline drugs market research report outlays comprehensive information on the ATP Binding Cassette Sub Family A Member 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the ATP Binding Cassette Sub Family A Member 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Metabolic Disorders, Genito Urinary System, and Ophthalmology which include the indications Atherosclerosis, Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes, Focal Segmental Glomerulosclerosis (FSGS), Diabetic Nephropathy, and Age Related Macular Degeneration. It also reviews key players involved in ATP Binding Cassette Sub Family A Member 1 targeted therapeutics development with respective active and dormant or discontinued products.
The ATP Binding Cassette Sub Family A Member 1 pipeline targets constitutes close to six molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, and Preclinical stages are 1, 2, and 2 respectively. Similarly, the universities portfolio in Phase I comprises 1 molecule.
ATP Binding Cassette Sub Family A Member 1 overview
ATP binding cassette subfamily A member 1 protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. This protein is a member of the ABC1 subfamily. Mutations in both alleles of this gene cause Tangier disease and familial high-density lipoprotein (HDL) deficiency.
For a complete picture of ATP Binding Cassette Sub Family A Member 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
